On September 9, 2026, certolizumab pegol received FDA Breakthrough Therapy Designation for APS pregnancy; Jane E. Salmon, MD, reviews the IMPACT trial results behind it.
Garima Sharma, MD, outlines validated cardiac risk scores for antenatal screening and the postpartum transitions needed to keep high-risk patients from being lost to follow-up.
Wen Shen, MD, outlines when to treat perimenopausal symptoms and which history-taking red flags should prompt earlier bone and cardiovascular screening or referral.